Tirzepatide — A Complete Research Reference

Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was developed by Eli Lilly and Company and received FDA approval in 2022 for type 2 diabetes (marketed as Mounjaro) and in 2023 for chronic weight management (marketed as Zepbound). The compound has since accumulated a substantial body of published Phase II and Phase III clinical trial data, and remains under active investigation for sleep apnea, heart failure with preserved ejection fraction, and metabolic dysfunction–associated steatohepatitis. This reference summarizes what the peer-reviewed human literature reports, what is known about the molecule itself, and what remains open.

Chemistry and Structure

Tirzepatide is a single-chain peptide of 39 residues built on a backbone derived from the native GIP sequence rather than the native GLP-1 sequence. Several modifications convert it from a GIP analog into a dual-receptor agonist with extended half-life. The peptide incorporates the non-natural amino acid 2-aminoisobutyric acid (Aib) at positions 2 and 13, which confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage — the same proteolytic vulnerability that limits the half-life of native incretins. A C20 fatty-diacid moiety is conjugated via a γGlu-2xOEG linker to a lysine residue at position 20. This lipidation enables non-covalent binding to circulating albumin, slowing renal clearance and extending plasma exposure into a once-weekly dosing window.

The molecular formula reported in regulatory filings is C₂₂₅H₃₄₈N₄₈O₆₈, with a molecular weight near 4814 Da. The molecule's affinity for the GIP receptor is comparable to native GIP, while affinity for the GLP-1 receptor is reduced relative to native GLP-1 — a deliberate engineering choice described in the medicinal-chemistry literature as biased agonism, with the resulting pharmacology emerging from the combined GIP and GLP-1 signaling rather than from maximal activation of either pathway alone.

The commercial product is supplied as a clear, colorless to slightly yellow solution in single-dose pre-filled pens (Mounjaro, Zepbound) at strengths of 2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL. Reference material used in research contexts is generally supplied as lyophilized powder requiring reconstitution.

Stability and Storage

Sealed pre-filled pens are labeled for refrigerated storage at 2–8 °C and may be kept at room temperature (below 30 °C) for up to 21 days according to the approved labeling. Light protection and avoidance of freezing are specified; frozen product is not to be used. Lyophilized reference material is typically stable for extended periods at −20 °C when sealed and protected from light and moisture.

Once reconstituted, peptide stability is sensitive to pH, buffer composition, and freeze-thaw cycles. Published handling notes typically recommend single freeze-thaw cycles where possible, with refrigerated storage at 2–8 °C for any working aliquot. Tirzepatide solutions are reported to be stable for short periods at refrigerator temperature, but rigorous stability-indicating HPLC data across long storage windows are not widely published for non-commercial preparations and should not be assumed to match the commercial product profile.

Researchers comparing analytical results across batches should verify peptide content, purity by HPLC, and absence of deamidation or oxidation side products, since these can shift potency in receptor-binding and cellular assays.

Pharmacology and Proposed Mechanisms

Tirzepatide is the first approved dual-incretin agonist. Both receptors it engages — GIP and GLP-1 — are class B G-protein–coupled receptors expressed in pancreatic islets and at lower density in adipose, brain, gut, and cardiovascular tissues. Native GIP and GLP-1 are secreted from enteroendocrine K and L cells, respectively, in response to nutrient ingestion, and they act in concert to augment insulin secretion in a glucose-dependent manner. The native peptides are rapidly degraded by DPP-4, giving them plasma half-lives of minutes.

The principal mechanistic claims associated with tirzepatide, as described in the peer-reviewed pharmacology literature, include the following. First, glucose-dependent insulin secretion from pancreatic β-cells, mediated by both GIP and GLP-1 receptor activation. Second, suppression of glucagon secretion, mediated primarily by GLP-1 receptor activation. Third, slowing of gastric emptying, mediated primarily by GLP-1 receptor activation in the central nervous system and gut. Fourth, central appetite suppression, with hypothalamic GLP-1 receptor signaling reducing food intake and contributing to weight loss. Fifth, GIP-mediated effects on adipose tissue and energy expenditure that remain mechanistically less well characterized than the GLP-1 arm but are proposed to contribute to tirzepatide's larger weight-loss signal compared with selective GLP-1 agonists.

The relative contribution of GIP versus GLP-1 signaling to the observed metabolic phenotype remains an active research question. GIP receptor pharmacology in metabolic disease has historically been controversial — both agonism and antagonism have been proposed as therapeutically useful in different model systems — and tirzepatide's clinical performance has reshaped that debate without fully settling it.

Human Clinical Trials

Tirzepatide has been evaluated in a large clinical program spanning type 2 diabetes (the SURPASS series) and obesity or overweight with weight-related complications (the SURMOUNT series), with additional trials in obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), and metabolic dysfunction–associated steatohepatitis (MASH).

SURPASS — Type 2 Diabetes

The SURPASS program comprised multiple Phase III trials in adults with type 2 diabetes. SURPASS-1 evaluated tirzepatide monotherapy against placebo. SURPASS-2, reported by Frías and colleagues in the New England Journal of Medicine in 2021, compared tirzepatide at 5, 10, and 15 mg weekly with semaglutide 1 mg weekly in patients with type 2 diabetes inadequately controlled on metformin; tirzepatide produced larger reductions in HbA1c and body weight than semaglutide at the doses tested. SURPASS-3 compared tirzepatide with insulin degludec, SURPASS-4 with insulin glargine, and SURPASS-5 examined tirzepatide as add-on to titrated insulin glargine. Across the program, HbA1c reductions in the tirzepatide arms were generally on the order of 1.8 to 2.6 percentage points from baseline, with concurrent body-weight reductions ranging from approximately 5 to 13 kg depending on dose, comparator, and baseline characteristics.

SURMOUNT — Obesity and Weight Management

The SURMOUNT program evaluated tirzepatide for chronic weight management. SURMOUNT-1, reported by Jastreboff and colleagues in the New England Journal of Medicine in 2022, enrolled adults with obesity or overweight with at least one weight-related complication, excluding diabetes; participants randomized to tirzepatide 15 mg weekly experienced a mean weight reduction of approximately 22.5 percent from baseline at 72 weeks, compared with approximately 2.4 percent in the placebo arm. SURMOUNT-2, reported by Garvey and colleagues in The Lancet in 2023, enrolled adults with type 2 diabetes and obesity and reported mean weight reductions of approximately 12.8 to 14.7 percent at 72 weeks across the 10 and 15 mg doses. SURMOUNT-3 evaluated tirzepatide as a follow-on to an intensive lifestyle-intervention lead-in; SURMOUNT-4 examined withdrawal after a treatment lead-in.

SURMOUNT-OSA and Other Indications

SURMOUNT-OSA evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity, reporting reductions in the apnea-hypopnea index that supported a 2024 FDA expansion of the Zepbound label to include OSA. SUMMIT examined tirzepatide in heart failure with preserved ejection fraction in patients with obesity, with reported improvements in symptom burden, exercise capacity, and reduction in a composite cardiovascular endpoint. Trials in metabolic dysfunction–associated steatohepatitis (MASH) and in cardiovascular outcomes (SURPASS-CVOT) are ongoing.

The integrated tirzepatide trial program is one of the larger metabolic-disease datasets in recent peptide therapeutics and is well-characterized in regulatory documents and the peer-reviewed literature.

Pharmacokinetics

Tirzepatide is administered by subcutaneous injection. Peak plasma concentrations occur approximately 24 to 72 hours after dosing. The elimination half-life is approximately 5 days, supporting once-weekly administration; steady state is reached after approximately four weeks of weekly dosing. Plasma exposure scales approximately proportionally with dose across the approved range. The molecule is primarily catabolized by proteolytic degradation into amino acids and small peptides rather than by hepatic cytochrome-P450 metabolism. Renal impairment, hepatic impairment, age, sex, race, ethnicity, and body weight have been characterized as not requiring dose adjustment in the approved labeling.

Population pharmacokinetic analyses, published in supporting trial documentation, describe between-subject variability in exposure but no clinically meaningful effect of demographic covariates on efficacy or safety endpoints across the studied range.

Safety Signals

The principal adverse-event profile reported across tirzepatide trials is gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain, generally mild to moderate in severity, most prominent during dose escalation, and largely transient. Hypoglycemia is uncommon as monotherapy because of the glucose-dependent insulinotropic mechanism, but increases when tirzepatide is combined with insulin or sulfonylureas.

Boxed warnings in the approved labeling describe the risk of thyroid C-cell tumors based on rodent findings with GLP-1 receptor agonists; tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Reported, less common safety signals across the program include pancreatitis, acute kidney injury (often dehydration-related, secondary to GI losses), cholelithiasis and acute gallbladder disease, hypersensitivity reactions, and diabetic retinopathy complications in patients with pre-existing retinopathy. Suicidal ideation has been monitored as a class issue across incretin therapeutics; published analyses have not established a causal association.

Long-term cardiovascular outcomes are being assessed in SURPASS-CVOT; the dedicated outcomes data are not yet fully reported. As with any approved chronic therapy, post-marketing safety surveillance continues to refine the profile.

Open Research Questions

Despite the depth of the existing clinical program, several questions recur in the published literature and in regulatory analyses.

• Relative contribution of GIP versus GLP-1 signaling. Mechanistic dissection of the dual-agonist phenotype in humans, particularly the GIP component, remains incomplete. Selective antagonist or analog studies are limited.
• Durability of weight loss after discontinuation. SURMOUNT-4 and related withdrawal designs indicate substantial weight regain after stopping therapy. The clinical and behavioral implications of chronic use, and the optimal strategies for transition or tapering, are not fully characterized.
• Body-composition outcomes. The proportion of weight loss attributable to fat mass versus lean mass, the trajectory of bone mineral density, and the implications for sarcopenia risk in older adults are active areas of investigation.
• Cardiovascular outcomes. Until SURPASS-CVOT reports, cardiovascular benefit in type 2 diabetes is inferred rather than demonstrated by a dedicated outcomes trial in the tirzepatide population.
• Pediatric and adolescent populations. Studies in younger populations with obesity are underway but are not yet fully reported, and the developmental safety profile is not yet established.
• Long-term safety beyond five years. Approved indications are chronic, but the published controlled-trial follow-up is mostly under two years; longer-term tolerability, immunogenicity, and rare-event signal detection require post-marketing data.
• Comparative effectiveness across the incretin class. Direct head-to-head data exist with semaglutide for selected endpoints (SURPASS-2). Comparisons with retatrutide (a triple agonist also in development) and with future class entrants will require dedicated trials.

Tirzepatide is a research compound on this site, supplied for laboratory and analytical work only. The clinical data summarized above pertain to the FDA-approved commercial products and are referenced for context. Nothing in this article constitutes medical advice or a recommendation for human use of laboratory-grade material; researchers are reminded that the regulatory framework for clinical administration differs in scope and oversight from that governing research-use compounds, and any work involving the molecule should be conducted under appropriate institutional review and within applicable jurisdictional rules.